Premium
Early‐mid treatment C‐reactive protein level is a prognostic factor in aggressive non‐Hodgkin’s lymphoma
Author(s) -
Herishanu Yair,
Perry Chava,
Braunstein Rony,
Metser Ur,
Goor Odelia,
Rogowski Ori,
Berliner Shlomo,
Polliack Aaron,
Naparstek Elizabeth
Publication year - 2007
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2007.00894.x
Subject(s) - medicine , lymphoma , c reactive protein , positron emission tomography , b symptoms , gastroenterology , aggressive lymphoma , chemotherapy , odds ratio , hodgkin lymphoma , oncology , risk factor , nuclear medicine , inflammation , rituximab
Background: In the light of an emerging role for early‐mid treatment 18 F‐deoxyfluoroglucose positron emission tomography (FDG‐PET) as an important prognostic indicator in aggressive non‐Hodgkin’s lymphoma (NHL) , we attempted to determine whether a simple parameter, such as the early‐mid treatment CRP (C‐reactive protein) level, could also be utilized as a significant prognostic factor in aggressive NHL. Patients and methods: Serum CRP levels were monitored in 55 patients with aggressive NHL. The lowest value of the early mid‐term CRP levels recorded was compared with the interim PET‐CT results, as well as with the clinical course and eventual outcome. Results: During chemotherapy, the lowest value of early‐mid treatment CRP levels significantly predicted the results of the interim FDG‐PET ( P = 0.04 with an odds ratio of 1.13). Patients who did not achieve an early‐mid treatment CRP level of <5 mg/L, had a shorter time to disease progression or relapse ( P = 0.001) as well as a reduced overall survival (OS) ( P = 0.016). Conclusions: The early‐mid treatment serum CRP level is a prognostic factor in aggressive NHL. Patients who do not achieve an early‐mid treatment level of <5 mg/L have quicker disease progression or earlier relapse and also appear to have an inferior OS.